ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Real-world effects of Yishen Tongbi decoction for rheumatoid arthritis: protocol for a prospective, observational, multicenter cohort study with validation against double-blind, randomized, controlled trial

Liu, Lijuan; Zhu, Fangfang; Xin, Yijun; Zhang, Lu; Hu, Congqi; Xu, Yanping; Zhang, Jinming; Liu, Lingjie; Chen, Guangxing*广东省人民医院; 广州中医药大学; 1
Frontiers in Pharmacology2024-2-12DOI: 10.3389/fphar.2024.1320578
20阅读
引用收藏
分享

摘要

Introduction: Rheumatoid arthritis (RA) is a globally challenging and refractory autoimmune disease, constituting a serious menace to human health. RA is characterized by recurrent pain and is difficult to resolve, necessitating prolonged medication for control. Yishen Tongbi decoction is a traditional Chinese herbal compound prescribed for treating RA. We have completed a 3-year RCT study that confirmed the clinical efficacy of Yishen Tongbi decoction for RA. Notably, we observed a faster clinical remission rate compared to MTX by week 4 of treatment. In our forthcoming study, we intend to conduct a comprehensive assessment of the efficacy and safety of Yishen Tongbi decoction in the real-world treatment of RA through a prospective study.Methods and analysis: This prospective, multicenter, real-world observational study will be conducted at two designated centers in China from October 2023 to August 2025. The study will include 324 patients with active rheumatoid arthritis. One group will receive Yishen Tongbi decoction combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The other group will receive standard treatment. Standard treatment can be further divided into subgroups: csDMARDs, targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), and biologic disease-modifying antirheumatic drugs (bDMARDs). In each group, the number of tender joints, number of swollen joints, pain score, patient global assessment, physician global assessment, disease activity index (DAS28-ESR or DAS28-CRP), clinical disease activity index (cDAI), simplified disease activity index (sDAI) and relevant laboratory data will be compared. Clinical indicators and disease activity of the patients will be assessed at baseline, week 4 and week 12 after the initiation of treatment. The primary outcome will be the American College of Rheumatology 20% improvement criteria (ACR20) attainment rate among patients at week 12 after treatment. Every adverse event will be reported.Ethics and dissemination: This study has been approved by the Ethics Committee of the first affiliated Hospital of Guangzhou University of traditional Chinese Medicine (NO.K-2023-009). The results of the study will be published in national and international peer-reviewed journals and at scientific conferences. The researchers will inform participants and other RA patients of the results through health education.Clinical Trial Registration: https://www.chictr.org.cn/index.html, identifier ChiCTR2300076073

学科与关键词

关键词
rheumatoid arthritisYishen Tongbi decoctionmethotrexatereal-world studyprotocol
相关
加载中…
  • Effectiveness of Yishen Tongbi decoction versus methotrexate in patients with active rheumatoid arthritis: A double-blind, randomized, controlled, non-inferiority trial
    Xu, Jia; Zhang, Lu; Xu, Yanping; Yu, Jiahui; Zhao, Lianyu; Deng, Hui; Li, Meiling; Zhang, Mingying; Lei, Xujie; Hu, Congqi; Jiao, Wei; Dai, Zhao; Liu, Lijuan*; Chen, Guangxing*PHYTOMEDICINE, 2023, 112: 154704.被引 3
  • Yunpi Qufeng Chushi Formula for Pre-Rheumatoid Arthritis: Study Protocol for a Multiple-Center, Double-Blind, Placebo-Controlled Randomized Controlled Trial
    Tang, Yujun; Li, Haichang; Huang, Lin; Wang, Qiao; Han, Yongmei; Wu, Huaxiang; Su, Xiao; Hou, Xiujuan; Huang, Chuanbing; Lin, Changsong; Tao, Qingwen; Tang, Jinyang; Cao, Wei*; Xie, Zhijun*; Wen, Chengping*Frontiers in Pharmacology, 2022, 13: 793394.被引 1
  • Conventional disease-modifying anti-rheumatic drugs combined with Chinese Herbal Medicines for rheumatoid arthritis: A systematic review and meta-analysis
    Han, Rong; Ren, Hong Cheng; Zhou, Sitong; Gu, Sherman; Gu, Yue-Yu; Sze, Daniel Man-yuen*; Chen, Meng-Hua*JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE, 2022, 12(5): 437-446.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2024-02-12
卷期
第 15 卷
页码
1320578
DOI
10.3389/fphar.2024.1320578
语言
ENGLISH
成果收录
SCIE
资助标注
Construction Project of Guangzhou Clinical Core Technology of Chinese Medicine; Guangzhou Municipal Science and Technology Bureau [202201020555]; National Natural Science Foundation of China [82305164]; Science and Technology Program of Guangzhou [2023A04J1170]; Traditional Chinese Medicine Bureau Of Guangdong Province [20221134]

作者

  • L

    Liu, Lijuan (第一作者)

    1 · guangzhou univ chinese med

  • Z

    Zhu, Fangfang

    guangdong prov hosp

查看全部 9 位作者收起作者
  • X

    Xin, Yijun

    1 · guangzhou univ chinese med

  • Z

    Zhang, Lu

    guangzhou univ chinese med

  • H

    Hu, Congqi

    1 · guangzhou univ chinese med

  • X

    Xu, Yanping

    1 · guangzhou univ chinese med

  • Z

    Zhang, Jinming

    1 · guangzhou univ chinese med

  • L

    Liu, Lingjie

    1 · guangzhou univ chinese med

  • C

    Chen, Guangxing (通讯)

    1 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417